AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

And this is how Cerevel's pipeline looked before the acquisition announcement. Since then, we have seen tavapadon deliver ...

Emraclidine was part of AbbVie’s acquisition of Cerevel last year, which also included Tavapadon, which recently reported positive Phase 3 results in Parkinson’s disease. The trial met its primary ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...